Circulating HPVDNA in patients undergoing transoral robotic surgery for oropharyngeal cancer: liquid biopsy could identify molecular residual disease.

IF 1.9 3区医学 Q2 OTORHINOLARYNGOLOGY

European Archives of Oto-Rhino-Laryngology Pub Date : 2025-06-01 Epub Date: 2025-01-25 DOI:10.1007/s00405-025-09218-x

Flaminia Campo, Francesca Paolini, Irene Terrenato, Giovanni Blandino, Valentina De Pascale, Oreste Iocca, Silvia Moretto, Valentina Manciocco, Antonello Vidiri, Aldo Venuti, Raul Pellini

{"title":"Circulating HPVDNA in patients undergoing transoral robotic surgery for oropharyngeal cancer: liquid biopsy could identify molecular residual disease.","authors":"Flaminia Campo, Francesca Paolini, Irene Terrenato, Giovanni Blandino, Valentina De Pascale, Oreste Iocca, Silvia Moretto, Valentina Manciocco, Antonello Vidiri, Aldo Venuti, Raul Pellini","doi":"10.1007/s00405-025-09218-x","DOIUrl":null,"url":null,"abstract":"Objectives: we evaluated the hypothesis that level of ctHPVDNA on the first postoperative day (POD-1); and at 15 days (POD-15) could be associated with the need for adjuvant therapy and the presence of recurrence.Materials and methods: this is a prospective observational study on biomarkers, focusing on the longitudinal monitoring of ctHPVDNA in a cohort of HPV-OPSCC patients undergoing TORS. Blood samples were collected according to the following schema: (1) pretreatment; (2) on first postoperative day (POD 1); and (3) at 15 days (POD 15). Plasma samples were analyzed with ddPCR assay comprising E6 of HPV16, HPV 33 and HPV 35.Results: Present study was conducted on 44 OPSCC patients and revealed a ctHPVDNA sensitivity of 100% (95%CI: 89-100%) in blood samples at first diagnosis. Data demonstrated a significant different of ctHPVDNA levels at POD-1 among patients who received observation vs. adjuvant treatment and among patients who remained disease-free at the last follow-up, compared to those who experienced recurrence. In the next years, studies on larger patients' surgical cohorts focused on ctHPVDNA levels at POD-1 and continued improvements in assay methodology could allow the implementation of ctHPVDNA in routine clinical use.Conclusion: Liquid biopsy could identify residual molecular disease after surgery and guide clinicians choosing adjuvant treatment.","PeriodicalId":11952,"journal":{"name":"European Archives of Oto-Rhino-Laryngology","volume":" ","pages":"3193-3199"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Archives of Oto-Rhino-Laryngology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00405-025-09218-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: we evaluated the hypothesis that level of ctHPVDNA on the first postoperative day (POD-1); and at 15 days (POD-15) could be associated with the need for adjuvant therapy and the presence of recurrence.

Materials and methods: this is a prospective observational study on biomarkers, focusing on the longitudinal monitoring of ctHPVDNA in a cohort of HPV-OPSCC patients undergoing TORS. Blood samples were collected according to the following schema: (1) pretreatment; (2) on first postoperative day (POD 1); and (3) at 15 days (POD 15). Plasma samples were analyzed with ddPCR assay comprising E6 of HPV16, HPV 33 and HPV 35.

Results: Present study was conducted on 44 OPSCC patients and revealed a ctHPVDNA sensitivity of 100% (95%CI: 89-100%) in blood samples at first diagnosis. Data demonstrated a significant different of ctHPVDNA levels at POD-1 among patients who received observation vs. adjuvant treatment and among patients who remained disease-free at the last follow-up, compared to those who experienced recurrence. In the next years, studies on larger patients' surgical cohorts focused on ctHPVDNA levels at POD-1 and continued improvements in assay methodology could allow the implementation of ctHPVDNA in routine clinical use.

Conclusion: Liquid biopsy could identify residual molecular disease after surgery and guide clinicians choosing adjuvant treatment.

查看原文本刊更多论文

口咽癌经口机器人手术患者循环HPVDNA：液体活检可识别分子残留疾病

目的：评估术后第一天ctHPVDNA水平（POD-1）的假设；而在15天（POD-15）时，可能与是否需要辅助治疗和是否存在复发有关。材料和方法：这是一项关于生物标志物的前瞻性观察性研究，重点是在接受tor治疗的HPV-OPSCC患者队列中进行ctHPVDNA的纵向监测。按以下模式采集血样：(1)预处理；(2)术后第一天（POD 1）；(3)第15天（POD 15）。采用ddPCR法对血浆样品进行分析，检测HPV16、hpv33和hpv35的E6。结果：本研究对44例OPSCC患者进行了研究，首次诊断时血液样本中ctHPVDNA的敏感性为100% （95%CI: 89-100%）。数据显示，与复发患者相比，接受观察治疗与辅助治疗的患者以及在最后一次随访时无病的患者的POD-1 ctHPVDNA水平存在显著差异。在接下来的几年里，对更大的患者手术队列的研究将重点放在POD-1的ctHPVDNA水平上，并且检测方法的持续改进可以使ctHPVDNA在常规临床应用中得以实施。结论：液体活检可鉴别术后残留的分子病变，指导临床医生选择辅助治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Archives of Oto-Rhino-Laryngology 医学-耳鼻喉科学

CiteScore

5.30

自引率

7.70%

发文量

537

审稿时长

2-4 weeks

期刊介绍： Official Journal of European Union of Medical Specialists – ORL Section and Board Official Journal of Confederation of European Oto-Rhino-Laryngology Head and Neck Surgery "European Archives of Oto-Rhino-Laryngology" publishes original clinical reports and clinically relevant experimental studies, as well as short communications presenting new results of special interest. With peer review by a respected international editorial board and prompt English-language publication, the journal provides rapid dissemination of information by authors from around the world. This particular feature makes it the journal of choice for readers who want to be informed about the continuing state of the art concerning basic sciences and the diagnosis and management of diseases of the head and neck on an international level. European Archives of Oto-Rhino-Laryngology was founded in 1864 as "Archiv für Ohrenheilkunde" by A. von Tröltsch, A. Politzer and H. Schwartze.